More than half of patients who stop GLP-1 weight-loss treatments are likely to restart them within a year, according to a study by the Endocrine Society. While many attempt to resume medications like Ozempic or Wegovy, research published in the Journal of Clinical Investigation Insight suggests that inconsistent dosing may reduce how effective these drugs are when patients restart treatment.
How many patients stop using GLP-1 medications?
Data from the Endocrine Society indicates high rates of treatment interruption among users of GLP-1 medications. By analyzing insurance records from more than 60,000 Americans, researchers identified specific patterns in how patients manage their prescriptions.
The study found that 4 in 10 patients stop taking their GLP-1 medications within the first year. This rate increases significantly over time, with nearly 6 in 10 patients stopping their treatment within two years. Researchers defined “discontinuation” as a gap of more than 60 days between prescription refills.
In clinical studies regarding GLP-1 adherence, researchers track “discontinuation” by looking for a gap of at least 60 days without a prescription refill.
What are the risks of restarting GLP-1 treatments?
While many patients return to GLP-1 therapy after a break, the transition may not be as seamless as expected. A study in the Journal of Clinical Investigation Insight highlights potential drawbacks to an “on-and-off” approach to weight management.
According to the research, inconsistent use of drugs such as Ozempic and Wegovy may reduce their effectiveness once a patient resumes the regimen. The study suggests that the biological benefits of these medications may rely heavily on steady, continuous administration.
The researchers noted that while effectiveness might decrease with inconsistent use, they did not identify any additional side effects caused by restarting the medication. The primary concern remains the potential loss of the drug’s therapeutic impact.
How should patients approach GLP-1 consistency?
Because effectiveness appears tied to regular use, medical experts suggest that GLP-1 medications should be viewed as long-term management tools rather than intermittent treatments. The study authors in the Journal of Clinical Investigation Insight emphasized that these drugs require a significant commitment.
The authors wrote that patients should discuss these medications with their doctors, specifically regarding their ability to maintain a strict schedule. They noted that GLP-1s may not be the ideal choice for individuals who struggle with the discipline required for daily or weekly medication.
If you are considering GLP-1 therapy, ask your healthcare provider about the long-term maintenance requirements and how a missed dose or a gap in treatment might affect your progress.
Frequently Asked Questions
Does restarting GLP-1 medication cause more side effects?
No. According to the Journal of Clinical Investigation Insight, no additional side effects were identified in patients who used the drugs inconsistently.
Why might GLP-1 drugs be less effective after a break?
The research suggests that the effectiveness of these medications may depend heavily on consistency in dosing.
How many people stop taking GLP-1s within two years?
An Endocrine Society study found that nearly 6 in 10 patients stop taking these medications within a two-year period.
To stay updated on the latest medical research and health trends, subscribe to our newsletter or explore our recent coverage on metabolic health.
